<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with a <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e> of stages I-II on the background of <z:hpo ids='HP_0000822'>hypertension</z:hpo> and/or cerebral <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> are characterized by energy insufficiency of the metabolism, as estimated by the activity of succinate dehydrogenase in peripheral blood lymphocytes </plain></SENT>
<SENT sid="1" pm="."><plain>Within the framework of randomized comparative investigation of the efficiency of actovegin and mexidol in the complex therapy of a <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e>, positive dynamics in reduction of the clinical semiology, restoration of cognitive processes in the brain, and reduction of the expression of subjective manifestations of the disease is established </plain></SENT>
<SENT sid="2" pm="."><plain>On this background, the administration of mexidol led to restoration of the energy exchange due to substrate effects of the Krebs cycle intermediates present in its structure </plain></SENT>
</text></document>